13 July 2022 - NICE has published evidence-based recommendations on the use of roxadustat (Evrenzo) for the treatment of adults with symptomatic anaemia associated with chronic kidney disease.

Roxadustat is recommended as an option for the treatment of adults with symptomatic anaemia associated with chronic kidney disease only if:

• They have stage 3 - 5 chronic kidney disease with no iron deficiency
• They are not on dialysis at the start of treatment
• Astellas provides roxadustat according to the commercial arrangement

Read NICE technology appraisal guidance